Pure Global
NCT06369142

Intracoronary Stenting and Additional Results Achieved by ShockWAVE Coronary Lithotripsy

Intracoronary Stenting and Additional Results Achieved by ShockWAVE Coronary Lithotripsy: A Randomized, Multicenter Study About the Additional Benefit of Coronary Lithotripsy
Deutsches Herzzentrum Muenchen·ClinicalTrials.gov·device·Device trialNot yet recruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Coronary Artery Disease
Drug/Device/Intervention
Intravascular lithotripsy (IVL)
Study type
Interventional
Intervention type
device
Sponsor & location
Primary sponsor
Deutsches Herzzentrum Muenchen
Location
Munich, Germany
Timeline & enrollment
Phase
N/A
Start date
Apr 30, 2024
End date
Jul 31, 2027
Enrollment
666 participants
Primary outcome

Combined endpoint of major cardiac and cerebrovascular events

Summary

The clinical trial is intended to evaluate the efficacy, safety and economic benefit of
 coronary lithotripsy compared to other additional procedures (cutting or super high pressure
 balloon angioplasty, ablative procedures) in lesion preparation and interventional treatment
 of severely calcified coronary stenoses.

ICD-10 classifications
Cardiovascular disease, unspecifiedAtherosclerotic cardiovascular disease, so describedAtherosclerotic heart diseaseAbnormal findings on diagnostic imaging of heart and coronary circulationCoronary vasodilators, not elsewhere classified
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06369142
Type
Device Trial
About this record

Access comprehensive clinical trial information for NCT06369142 through Pure Global AI's free database. This phase not specified trial is sponsored by Deutsches Herzzentrum Muenchen and is currently Not yet recruiting. The study focuses on Coronary Artery Disease. Target enrollment is 666 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.